A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer

BACKGROUND: Everolimus significantly improves progression-free survival (PFS) and has been approved to use in aromatase inhibitor pretreated patients with hormone receptor positive advanced breast cancer. Metformin has been shown to inhibit mTOR pathway, with more favorable safety profile, leading t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Zhao, Yannan, Gong, Chengcheng, Wang, Zhonghua, Zhang, Jian, Wang, Leiping, Zhang, Sheng, Cao, Jun, Tao, Zhonghua, Li, Ting, Wang, Biyun, Hu, Xichun
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5663590/
https://ncbi.nlm.nih.gov/pubmed/29137418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20478
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados